NA+-K+-2CL-TRANSPORTER OF HENLE LOOP AS A TARGET FOR THE PHARMACOLOGICAL INTERVENTION


Cite item

Full Text

Abstract

The role of Na+-K+-2Cl-transporter of Henle loop in the physiology and pathology, including its importance as a target for loop diuretics, are discussed.

About the authors

- -

References

  1. Серов В.В., Пальцев М.А. Почки и артериальная гипертензия. М.: Медицина, 1993.
  2. Наточин Ю.В. (ред.) Физиология почки и водно-солевого обмена. СПб.: Наука, 1993.
  3. Наточин Ю.В. Механизмы мочеобразования. В: Тареева И.Е. (ред.) Нефрология. Руководство для врачей. М.: Медицина, 2000; 24-48.
  4. Кутырина И.М. Почки и водно-электролитный обмен. В: Тареева И.Е. (ред.) Нефрология. Руководство для врачей. М.: Медицина, 2000; 49-61.
  5. Haas M., Forbush B. The Na-K-Cl cotransporter of secretory epithelia. Annu. Rev. Physiol. 2000; 62: 515-534.
  6. Obermuller N., Kunchaparty S., Ellison D.H. et al. Expression of the Na-K-2Cl cotransporter by macula densa and thick ascending limb cells of rat and rabbit nephron. J. Clin. Invest 1996; 98: 635-640.
  7. Molony D.A., Reeves W.B., Andreoli T.E. Na+:K+:2Cl- cotransport and the thick ascending limb. Kidney Int. 1989; 36(3): 418-426.
  8. Fenton M.A., Knepper M.A. Mouse models and the urinary concentrating mechanism in the new millennium. Physiol. Rev. 2007; 1083-1112.
  9. Plato C.F., Stoos B.A., Wang D. et al. Endogenous nitric oxide inhibits chloride transport in the thick ascending limb. Am. J. Physiol. Renal. Physiol. 1999; 276: F159-F163.
  10. Ortiz P.A., Hong N.J., Garvin J.L. Luminal flow induces eNOS activation and translocation in the rat thick ascending limb. Am. J. Physiol. Renal Physiol. 2004; 287: F274-F280.
  11. Silva G., Beierwaltes W.H., Garvin J.L. Extracellular ATP stimulates NO production in rat thick ascending limb. Hypertension 2006; 47: 563-567.
  12. Ortiz P.A., Garvin J.L. NO inhibits NaCl absorption by rat thick ascending limb through activation of cGMP-stimulated phosphodiesterase. Hypertension 2001; 37: 467-471.
  13. Ujiie K., Yuen J., Hogarth L. et al. Localization and regulation of endothelial NO synthase mRNA expression in rat kidney. Am. J. Physiol. Renal Fluid Electrolyte Physiol. 1994; 267: F296-F302.
  14. Plato C.F., Shesely E.G., Garvin J.L. eNOS mediates L-arginine induced inhibition of thick ascending limb chloride flux. Hypertension 2000; 35: 319-323.
  15. Plato C.F., Pollock D.M., Garvin J.L. Endothelin inhibits thick ascending limb chloride flux via ETB receptor-mediated NO release. Am. J. Physiol. Renal Physiol. 2000; 279: F326-F333.
  16. Plato C.F., Garvin J.L. α2-Adrenergic-mediated tubular NO production inhibits thick ascending limb chloride absorption. Am. J. Physiol. Renal Physiol. 2001; 281: F679-F686.
  17. Herrera M., Ortiz P.A., Garvin J.L. Regulation of thick ascending limb transport: role of nitric oxide. Am. J. Physiol. Renal. Physiol. 2006; 290: F1279-F1274.
  18. Leyssac P.P., Karlsen F.M., Holstein-Rathlou N.H. et al. On determinants of glomerular filtration rate after inhibition of proximal tubular reabsorption. Am J Physiol Regul. Integr. Comp. Physiol. 1994; 266: R1544-R1550.
  19. Lee D.L., Sasser J.M., Hobbs J.L. et al. Posttranslational regulation of NO synthase activity in the renal medulla of diabetic rats. Am. J. Physiol. Renal. Physiol 2005; 288: F82-F90.
  20. Ortiz P., Stoos B.A., Hong N.J. et al. High-salt diet increases sensitivity to NO and eNOS expression but not NO production in THALs. Hypertension 2003; 41: 682-687.
  21. Kim G.H., Ecelbarger C.A., Mitchell C. et al. Vasopressin increases Na-K-2Cl co-transporter expression in thick ascending limb of Henle's loop. Am. J. Physiol. Renal. Physiol 1999; 276: F96-F103.
  22. Agre P. Homer W. Smith award lecture. Aquaporin water channels in kidney. J. Am. Soc. Nephrol. 2000; 11: 764-777.
  23. Knepper M.A. Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin. Am. J. Physiol. Renal. Physiol. 1997; 272: F3-F12.
  24. Hebert R.L., Jacobson H.R., Breyer M.D. PGE2 inhibits AVP-induced water flow in cortical collecting ducts by protein kinase C activation. Am. J. Physiol. Renal Fluid. Electrolyte. Physiol 1990; 259: F318-F325.
  25. Heerdink E.R., Leufkens H.G., Herings R.M. et al. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med 1990; 158: 1108-1112.
  26. Brater D.C. Diuretic therapy. N. Engl. J. Med. 1998; 339: 387-395.
  27. Shankar S.S., Brater D.G. Loop diuretics: from the Na-K-2Cl transporter to clinical use. Am. J. Physiol. Renal. Physiol. 2003; 284: 11-21.
  28. Lyseng-Williamson K.A. Torasemide prolonged release. Drugs. 2009;69(10): 1363-1372.
  29. Muller K., Gamba G., Jaquet F. et al. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV - efficacy and quality of life. Eur. J. Heart Fail. 2003; 5(6): 793-801.
  30. Spannheimer A., Muller K., Falkenstein P. et al. Long-term diuretic treatment in heart failure: are there differences between furosemide and torasemide? Praxis. 2002; 91(37): 1467-1475.
  31. Rudy D.W., Voelker J.R., Greene P.K. et al. Loop diuretics for chronic renal insufficiency: a continuous infusion is more efficacious than bolus therapy. Ann. Intern. Med. 1991; 115: 360-366.
  32. Boesken W.H., Kult J. High-dose torasemide, given once daily intravenously for one week, in patients with advanced chronic renal failure. Clin. Nephrol. 1997; 48(1): 22-28.
  33. Fliser D., Schroter M., Neubeck M. et al. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int. 1994; 46(2): 482-488.
  34. Whelton A., Smith W.B., Wallin J.D. et al. Long-term treatment with oral torasemide and its effect on body weight and fluid balance in patients with chronic renal insufficiency. Am. J. Ther. 1996; 3(11): 743-749.
  35. Vasavada N., Saha C., Agarwal R. A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease. Kidney Int. 2003; 64(2): 632-640.
  36. Lopez B., Gonzalez A., Hermida N. et al. Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide. Kidney Int. Suppl. 2008; 111: S19-S23.
  37. Veeraveedu P.T., Watanabe K., Ma M. et al. Comparative effects of torasemide and furosemide in rats with heart failure. Biochem. Pharmacol. 2007; 23: 143-148.
  38. Veeraveedu P.T., Watanabe K., Ma M. et al. Comparative effects of torasemide and furosemide in rats with heart failure. Biochem. Pharmacol. 2008; 75: 649-659.
  39. Vargas Hein O., Staegemann M., Wagner D. et al. Torsemide versus furosemide after continuous renal replacement therapy due to acute renal failure in cardiac surgery patients. Ren. Fail. 2005; 27(4): 385-392.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies